Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance

Third Quarter 2022 Revenues of $32.2 Million, a 40% Increase Compared to Prior Year Period; Reaping the Benefits of the Acquired IgG PortfolioStrong Results Represent Completion of the Company’s...
November 16, 2022 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022

REHOVOT, Israel, and HOBOKEN, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty...
November 07, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT

Trial Recruitment Beginning to Accelerate; 30 Patients Enrolled and Treated to DateIndependent Data Safety Monitoring Board (DSMB) Recommends Study Continuation Without Modification for Fourth Time...
October 26, 2022 07:00 ET | Source: Kamada Ltd.

Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference

REHOVOT, Israel and HOBOKEN, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty...
October 19, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Awarded $22 Million Extension of Canadian Supply Tender

Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products Acquired in 2021Supply Extension Secures Ongoing Sales of Approximately $7.5 Million Per Year for...
August 17, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance

Second Quarter 2022 Revenues were $23.6 Million; First Half 2022 Revenues of $51.7 Million Increased 5% Year-Over-YearFirst Half 2022 Adjusted EBITDA of $4.6 Million; Excluding Labor Strike Related...
August 10, 2022 07:00 ET | Source: Kamada Ltd.

Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022

REHOVOT, Israel and HOBOKEN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty...
July 15, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

REHOVOT, Israel, July 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics,...
July 06, 2022 06:00 ET | Source: Kamada Ltd.

Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement

Procurement Agreement Following a New Tender Won from an International Organization Operating Principally in Latin AmericaProduct Supply Expected During the Fourth Quarter of 2022 and the First Half...
June 15, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma-Derived Therapeutics Market

REHOVOT, Israel, and HOBOKEN, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty...